Zevra Therapeutics

Historical price data

Zevra Therapeutics is a purpose-driven rare disease company with a dual focus on commercial execution and late-stage clinical development. Its strategy involves following scientific data to build compelling regulatory narratives that address significant unmet patient needs. With a seasoned leadership team and a pipeline anchored in rare neurological and genetic disorders, Zevra aims to become a leader in the orphan drug space by advancing transformative therapies.

Zevra's core approach is strategic rather than technological, focusing on identifying promising therapeutic candidates for rare diseases and advancing them through development by building data-driven, patient-centric regulatory narratives.

5 drugs in pipeline, 2 in Phase 3

Total raised: $30M

Zevra's competition is indication-specific: it faces minimal direct competition in NPC (arimoclomol) and VEDS (celiprolol), where it aims to be first-to-market. In Urea Cycle Disorders, it competes with other approved nitrogen-scavenging agents. Its differentiation is its focused rare disease expertise and strategy of pursuing first- or best-in-class therapies for high-unmet-need conditions.